Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemifloxacin

Drug Profile

Gemifloxacin

Alternative Names: ARB-FV0127; Factive; Gemifloxacin mesylate; LB 20304; LB 20304a; SB 265805

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LG Life Sciences
  • Developer Abbott Canada; Chiesi USA; LG Chem; Menarini; Pfizer
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Imines; Naphthyridines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Respiratory tract infections; Urinary tract infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)
  • 26 Jul 2016 The US FDA approved label for gemifloxacin carries a boxed warning
  • 22 Oct 2014 Launched prior to this date for Bacterial infections in Brazil, Chile, Mexico, South Africa & Turkey (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top